Salute e Benessere

IBA Notice of Half Year 2024 Results and Conference Call

HY24 results webcast to take place onThursday, 29 August 2024 at 3pm CEST Louvain-la-Neuve, Belgium, 1 August 2024- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2024 onThursday, 29 August 2024 at 7am CEST.Conference Call Information IBA's management team will host a conference call and webcast conducted in English to present the half year...
Nasdaq GlobeNewswire
01/08/2024

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the…

Valneva obtains exclusive worldwide license for LimmaTech's S4VShigellavaccine candidate and adds an attractive Phase 2 clinical asset to Valneva's R&D pipelineLimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2Valneva will host a live webcast on this announcement at 3 p.m. CEST/9 a.m. EDT today. Please refer to this link: ...
Nasdaq GlobeNewswire
01/08/2024

Pharming Group reports second quarter and first half 2024 financial results and…

Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023On...
Nasdaq GlobeNewswire
01/08/2024

Fagron delivers strong performance with 16% topline growth and 17% increase in…

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2024. Key Highlights Strong topline performance with 15.5% reported revenue growth (15.3% at Constant Exchange Rates...
Nasdaq GlobeNewswire
01/08/2024

Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of…

Frederick Beddingfield, MD, PhD, serving as Chairperson of the board of directors of Sagesse Bio, is an internationally renowned dermatologist and expert in biopharma and the aesthetics industry, who has led the development of global leading brands such as BOTOX®, JUVEDERM®, LATISSE® and KYBELLA®. He served as Chief Medical Officer of Allergan Medical and Kythera, and as CEO of Sienna Bio and Kira Pharmaceuticals, and currently serves on the board of directors of Cytrellis Biosystems. Dr…
PR Newswire
01/08/2024

Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion…

Prestige Biopharma has already established licensing agreements with major pharmaceutical partners for global marketing and sales. These agreements are set to generate immediate milestone payments and provide early revenue for the company. Negotiations are also underway to ensure a strong market entry for Tuznue® in Europe. Prestige Biopharma has already established licensing agreements with major pharmaceutical partners for global marketing and sales. These agreements are set to generate...
PR Newswire
01/08/2024

Endo Announces Effectiveness of Form S-1 Registration Statement for Existing…

Endo, which is focused on creating long-term value for stakeholders through a diversified portfolio of on-market medicines and a pipeline of innovative and differentiated product candidates, is targeting to have the Company's shares of common stock begin trading on the New York Stock Exchange (NYSE) later in 2024, subject to required approvals and other customary conditions. Endo, which is focused on creating long-term value for stakeholders through a diversified portfolio of on-market...
PR Newswire
31/07/2024

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates…

"Jazz's record revenues of over $1 billion in the second quarter were driven by strong execution and increased demand for our key growth drivers, Xywav, Epidiolex and Rylaze. Our launch preparations are well underway for zanidatamab, which was recently granted Priority Review in BTC, and we are pleased to have initiated the Phase 3 EmpowHER trial in HER2-positive breast cancer in patients whose disease has progressed after T-DXd treatment," said Bruce Cozadd, chairman and chief…
PR Newswire
31/07/2024

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.01 2million of short-term deposits and €9.0 3million of long-term deposits as of December 31, 2023.On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng) for an amount of approximately €20.1 million.No Revenues recorded in H1 2024, compared to €1.9 million for the...
Nasdaq GlobeNewswire
31/07/2024

EUROBIO SCIENTIFIC: CONCLUSION OF AN AGREEMENT BETWEEN EUROBIO SCIENTIFIC AND A…

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO ANY US PERSON, OR TO ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. CONCLUSION OF AN AGREEMENT BETWEEN EUROBIO SCIENTIFIC AND A CONSORTIUM LED BY EUROBIO SCIENTIFIC'S TEAM OF ENTREPRENEURS AND MANAGERS, IK PARTNERS AND NEXTSTAGE AM WITH A VIEW TO FILE A VOLUNTARY TENDER OFFER AT A PRICE OF €25.30 PER EUROBIO SCIENTIFIC SHARE...
Nasdaq GlobeNewswire
31/07/2024

Eurobio Scientific: FIRST HALF 2024, A SOLID START TO THE FINANCIAL YEAR IN AN…

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO ANY US PERSON, OR TO ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. FIRST HALF 2024, A SOLID START TO THE FINANCIAL YEAR IN AN UNCERTAIN ENVIRONMENTPROPOSED TENDER OFFERHalf-year revenue growth of +24% (+12% excluding the effects of changes in the scope of consolidation linked to the acquisitions of DID and Alpha...
Nasdaq GlobeNewswire
31/07/2024

Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support…

The atmosphere of the exchange was enthusiastic and congenial. Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang, along with other executives, visited Medicilon's Pudong Chuansha Park. They were welcomed by Medicilon's CEO Chunlin Chen and key team members. The atmosphere of the exchange was enthusiastic and congenial. Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang, along with other executives, visited Medicilon's Pudong…
PR Newswire
31/07/2024

Liquid Biopsy Market: Rising Adoption to Propel 11.21% CAGR by 2031 | SkyQuest…

Furthermore, the increasing adoption of liquid biopsy signals an expansion in generalized medicine and cancer precision. These new diagnostic methods offer advantages over traditional biopsies analyzes body by real-time monitoring of disease progression and treatment response, providing timely intervention strategies such as early detection and prioritization. The liquid biopsy market is poised for further growth with advances in technology, expanded research efforts, driven by increased…
PR Newswire
31/07/2024

Molecular Diagnostic Market to Attain USD 37.00 Billion in 2031 As Genetic…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/molecular-diagnostics-market Molecular Diagnostics Market Overview: Segments covered in Molecular Diagnostics Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/molecular-diagnostics-market Molecular Diagnostics' Contribution to Personalized Medicine and Disease Detection Among the many goods and...
PR Newswire
31/07/2024

Advanced Wound Care Market to Reach USD 10.8 Billion by 2031, Driven by…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/advanced-wound-care-market Advanced Wound Care Market Overview: Segments covered in Advanced Wound Care Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/advanced-wound-care-market Rising Inclination towards Smart Wound Dressings to Accelerate Healing Process Supports Market Growth Smart dressings...
PR Newswire
31/07/2024

O'Ryan.Health Launches Groundbreaking Parent-Led Pediatric Studies Utilizing…

The institutional review board approved study involves healthy children and children with a JDM diagnosis. Capillary blood is drawn on a predetermined schedule using virtually painless TAP Micro devices. Guided by animated Superhero Scientists and comic book "mission reports" of their results, children take an active role in their healthcare journey and learn about their immune health. The institutional review board approved study involves healthy children and children with a JDM…
PR Newswire
31/07/2024

Visionet rebrands as a future-ready engineering partner

While its brand identity is evolving, its core values remain steadfast. Visionet continues to uphold problem-solving, agility, adaptability, and customer-centricity. Visionet is committed to delivering the high-quality products and services its customers have come to expect. While its brand identity is evolving, its core values remain steadfast. Visionet continues to uphold problem-solving, agility, adaptability, and customer-centricity. Visionet is committed to delivering the high-quality...
PR Newswire
31/07/2024

Essence SmartCare Integrates its Ultracompact Umbrella mPERS with North…

In the event of a medical emergency or safety threat, it is critical that monitoring services react in real-time, any time. Integrating Umbrella mPERS into their software allows these leading monitoring providers to sync all events and notifications with users so that in case of an emergency, providers can communicate directly with the user and first responders can be notified immediately. "Boosting Umbrella mPERS' availability throughout the country is a pivotal step forward in...
PR Newswire
31/07/2024

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for…

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers ®with SupraAntigen ®monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in CNSmorADC demonstrated significant synergies, substantially increasing blood brain barrier penetration and potency to inhibit protein aggregation...
Nasdaq GlobeNewswire
31/07/2024

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for…

“The FDA's decision to grant rare pediatric drug designation to VCN-01 highlights the urgent need for new treatment options for pediatric patients with retinoblastoma,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We are encouraged by this important step forward and, in parallel, continue to work closely with leading physicians and regulatory agencies to refine our clinical strategy for VCN-01 as an adjunct to chemotherapy in pediatric patients with advanced...
Nasdaq GlobeNewswire
31/07/2024

PROCESSED RED MEAT RAISES THE RISK OF DEMENTIA; SWAPPING IT FOR NUTS AND BEANS…

PHILADELPHIA, July 31, 2024 /PRNewswire/ -- People who eat at least 1/4 serving of bacon, bologna or other processed red meat a day (about two servings a week) have a higher risk of dementia than those who eat less than 1/10 of a serving a day (about three servings a month), according to a study reported today at the Alzheimer's Association International Conference® (AAIC®) 2024, in Philadelphia and online. PHILADELPHIA,July 31, 2024/PRNewswire/ -- People who eat at least 1/4 serving of...
PR Newswire
31/07/2024

Aily Labs Expands Global Footprint with New York Office Launch and Strengthens…

Jason Rizzo, joining as Senior Vice President of Sales, brings over 20 years of experience in B2B cloud software. With a proven track record in complex sales landscapes and strategic partnerships, Rizzo will be instrumental in expanding Aily Labs' global market reach and driving business growth. Previously, Rizzo served as Vice President of Global Life Science Strategy & Partnerships for InsightRX and led R&D and Quality for Veeva Systems. Jason Rizzo , joining as Senior Vice President…
PR Newswire
31/07/2024

Immatics Appoints Alise Reicin to Board of Directors

Houston, Texas and Tuebingen, Germany, July 31, 2024–Immatics N.V.(NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including...
Nasdaq GlobeNewswire
31/07/2024

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by…

For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency terms compared to Q2 2023.Generics business grows across all regions – increased in local currency terms by 16% in the U.S., 8% in Europe and 22% in International Markets, compared to Q2 2023.AUSTEDO – continued growth, U.S. revenue of $407 million in Q2 2024, an increase of 32% compared to Q2 2023;...
Nasdaq GlobeNewswire
31/07/2024
Altri  Comunicati